B cell lymphoma 6 promotes hepatocellular carcinoma progression by inhibiting tumor infiltrating CD4+T cell cytotoxicity through ESM1

Immunotherapy exhibited potential effects for advanced hepatocellular carcinoma, unfortunately, the clinical benefits are often countered by cancer adaptive immune suppressive response. Uncovering the mechanism how cancer cells evade immune surveillance would help to develop new immunotherapy approa...

Full description

Saved in:
Bibliographic Details
Published in:NPJ precision oncology 2024-07, Vol.8 (1), p.139-16, Article 139
Main Authors: Li, Jiatao, Feng, Juan, Li, Ziyong, Ni, Yuanli, Liu, Limei, Lei, Xia, Chai, Zixuan, Zhuang, Na, Xu, Jiake, He, Yongpeng, Shan, Juanjuan, Qian, Cheng
Format: Article
Language:English
Subjects:
631/67/580/1884
692/4028/67/395
Antigens
Cancer Research
Cancer therapies
Cell death
Clinical outcomes
Cytokines
Cytotoxicity
DNA repair
Gene Therapy
Genomes
Human Genetics
Immunotherapy
Internal Medicine
Leukemia
Liver cancer
Lymphocytes
Lymphoma
Medicine
Medicine & Public Health
Oncology
Patients
Proteins
Transcription factors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c378t-73da74e349aeb32fb777ec235b47af15a96d015f0f75c690d69369f9e46867fe3
container_end_page 16
container_issue 1
container_start_page 139
container_title NPJ precision oncology
container_volume 8
creator Li, Jiatao
Feng, Juan
Li, Ziyong
Ni, Yuanli
Liu, Limei
Lei, Xia
Chai, Zixuan
Zhuang, Na
Xu, Jiake
He, Yongpeng
Shan, Juanjuan
Qian, Cheng
description Immunotherapy exhibited potential effects for advanced hepatocellular carcinoma, unfortunately, the clinical benefits are often countered by cancer adaptive immune suppressive response. Uncovering the mechanism how cancer cells evade immune surveillance would help to develop new immunotherapy approaches and combination therapy. In this article, by analyzing the transcriptional factors which modulate the differentially expressed genes between T cell infiltration high group and low group, we identified oncoprotein B cell lymphoma 6 (BCL6) suppresses the infiltration and activation of tumor infiltrating T lymphocytes, thus correlated with poorer clinical outcome. By using antibody deletion experiment, we further demonstrated that CD4 + T cells but not CD8 + T cells are the main lymphocyte population suppressed by Bcl6 to promote HCC development. Mechanistically, BCL6 decreases cancer cell expression of pro-inflammatory cytokines and T lymphocyte chemokines such as IL6, IL1F6, and CCL5. Moreover, BCL6 upregulates Endothelial cell-specific molecule 1 (ESM1) to inhibit T lymphocyte recruitment and activation possibly through ICAM-1/LFA-1 signaling pathway. Our findings uncovered an unappreciated paracrine mechanism how cancer cell-derived BCL6 assists cancer cell immune evasion, and highlighted the role of CD4 + T cells in HCC immune surveillance.
doi_str_mv 10.1038/s41698-024-00625-7
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_c974027dd938497a9f3e4f2dc6f25c57</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_c974027dd938497a9f3e4f2dc6f25c57</doaj_id><sourcerecordid>3075376376</sourcerecordid><originalsourceid>FETCH-LOGICAL-c378t-73da74e349aeb32fb777ec235b47af15a96d015f0f75c690d69369f9e46867fe3</originalsourceid><addsrcrecordid>eNp9Us2K1TAYLaI4w3VewIUE3AhSzV-TZiXOddSBEReO4C6kadLm0jbXJBXvA_jeprfjOONCCCR838k5OV9OUTxF8BWCpH4dKWKiLiGmJYQMVyV_UJxiInjJWf3t4Z3zSXEW4w5CiOoKYcYeFyekFhWjBJ8Wv86BNsMAhsO47_2oAAP74EefTAS92avkl_Y8qAC0CtpNCyYjumBidH4CzQG4qXeNS27qQJpHH3LBuiEFdSxt39GX16uIPiSf_E-nXTqA1Ac_dz24-PIJPSkeWTVEc3azb4qv7y-utx_Lq88fLrdvr0pNeJ1KTlrFqSFUKNMQbBvOudGYVA3lyqJKCdZCVFloeaWZgC0ThAkrDGU149aQTXG58rZe7eQ-uFGFg_TKyWPBh06qkJwejNSCU4h52wpSU8GVsMRQi1vNLK50xTPXm5VrPzejabWZsuPhHun9zuR62fkfEiGMYf63zPDihiH477OJSY4uLoNSk_FzlATyinC2rE3x_B_ozs9hyrNaULSuKc1eNwVeUTr4GIOxt69BUC6pkWtqZFaXx9TIxcezuz5ur_zJSAaQFRBza-pM-Kv9H9rf-V_PYg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3074884469</pqid></control><display><type>article</type><title>B cell lymphoma 6 promotes hepatocellular carcinoma progression by inhibiting tumor infiltrating CD4+T cell cytotoxicity through ESM1</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Li, Jiatao ; Feng, Juan ; Li, Ziyong ; Ni, Yuanli ; Liu, Limei ; Lei, Xia ; Chai, Zixuan ; Zhuang, Na ; Xu, Jiake ; He, Yongpeng ; Shan, Juanjuan ; Qian, Cheng</creator><creatorcontrib>Li, Jiatao ; Feng, Juan ; Li, Ziyong ; Ni, Yuanli ; Liu, Limei ; Lei, Xia ; Chai, Zixuan ; Zhuang, Na ; Xu, Jiake ; He, Yongpeng ; Shan, Juanjuan ; Qian, Cheng</creatorcontrib><description>Immunotherapy exhibited potential effects for advanced hepatocellular carcinoma, unfortunately, the clinical benefits are often countered by cancer adaptive immune suppressive response. Uncovering the mechanism how cancer cells evade immune surveillance would help to develop new immunotherapy approaches and combination therapy. In this article, by analyzing the transcriptional factors which modulate the differentially expressed genes between T cell infiltration high group and low group, we identified oncoprotein B cell lymphoma 6 (BCL6) suppresses the infiltration and activation of tumor infiltrating T lymphocytes, thus correlated with poorer clinical outcome. By using antibody deletion experiment, we further demonstrated that CD4 + T cells but not CD8 + T cells are the main lymphocyte population suppressed by Bcl6 to promote HCC development. Mechanistically, BCL6 decreases cancer cell expression of pro-inflammatory cytokines and T lymphocyte chemokines such as IL6, IL1F6, and CCL5. Moreover, BCL6 upregulates Endothelial cell-specific molecule 1 (ESM1) to inhibit T lymphocyte recruitment and activation possibly through ICAM-1/LFA-1 signaling pathway. Our findings uncovered an unappreciated paracrine mechanism how cancer cell-derived BCL6 assists cancer cell immune evasion, and highlighted the role of CD4 + T cells in HCC immune surveillance.</description><identifier>ISSN: 2397-768X</identifier><identifier>EISSN: 2397-768X</identifier><identifier>DOI: 10.1038/s41698-024-00625-7</identifier><identifier>PMID: 38956432</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/580/1884 ; 692/4028/67/395 ; Antigens ; Cancer Research ; Cancer therapies ; Cell death ; Clinical outcomes ; Cytokines ; Cytotoxicity ; DNA repair ; Gene Therapy ; Genomes ; Human Genetics ; Immunotherapy ; Internal Medicine ; Leukemia ; Liver cancer ; Lymphocytes ; Lymphoma ; Medicine ; Medicine &amp; Public Health ; Oncology ; Patients ; Proteins ; Transcription factors</subject><ispartof>NPJ precision oncology, 2024-07, Vol.8 (1), p.139-16, Article 139</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c378t-73da74e349aeb32fb777ec235b47af15a96d015f0f75c690d69369f9e46867fe3</cites><orcidid>0000-0002-0640-1652 ; 0009-0006-2546-7602 ; 0000-0003-1500-9991 ; 0000-0002-9277-6855</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11220024/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3074884469?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38956432$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Jiatao</creatorcontrib><creatorcontrib>Feng, Juan</creatorcontrib><creatorcontrib>Li, Ziyong</creatorcontrib><creatorcontrib>Ni, Yuanli</creatorcontrib><creatorcontrib>Liu, Limei</creatorcontrib><creatorcontrib>Lei, Xia</creatorcontrib><creatorcontrib>Chai, Zixuan</creatorcontrib><creatorcontrib>Zhuang, Na</creatorcontrib><creatorcontrib>Xu, Jiake</creatorcontrib><creatorcontrib>He, Yongpeng</creatorcontrib><creatorcontrib>Shan, Juanjuan</creatorcontrib><creatorcontrib>Qian, Cheng</creatorcontrib><title>B cell lymphoma 6 promotes hepatocellular carcinoma progression by inhibiting tumor infiltrating CD4+T cell cytotoxicity through ESM1</title><title>NPJ precision oncology</title><addtitle>npj Precis. Onc</addtitle><addtitle>NPJ Precis Oncol</addtitle><description>Immunotherapy exhibited potential effects for advanced hepatocellular carcinoma, unfortunately, the clinical benefits are often countered by cancer adaptive immune suppressive response. Uncovering the mechanism how cancer cells evade immune surveillance would help to develop new immunotherapy approaches and combination therapy. In this article, by analyzing the transcriptional factors which modulate the differentially expressed genes between T cell infiltration high group and low group, we identified oncoprotein B cell lymphoma 6 (BCL6) suppresses the infiltration and activation of tumor infiltrating T lymphocytes, thus correlated with poorer clinical outcome. By using antibody deletion experiment, we further demonstrated that CD4 + T cells but not CD8 + T cells are the main lymphocyte population suppressed by Bcl6 to promote HCC development. Mechanistically, BCL6 decreases cancer cell expression of pro-inflammatory cytokines and T lymphocyte chemokines such as IL6, IL1F6, and CCL5. Moreover, BCL6 upregulates Endothelial cell-specific molecule 1 (ESM1) to inhibit T lymphocyte recruitment and activation possibly through ICAM-1/LFA-1 signaling pathway. Our findings uncovered an unappreciated paracrine mechanism how cancer cell-derived BCL6 assists cancer cell immune evasion, and highlighted the role of CD4 + T cells in HCC immune surveillance.</description><subject>631/67/580/1884</subject><subject>692/4028/67/395</subject><subject>Antigens</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Cell death</subject><subject>Clinical outcomes</subject><subject>Cytokines</subject><subject>Cytotoxicity</subject><subject>DNA repair</subject><subject>Gene Therapy</subject><subject>Genomes</subject><subject>Human Genetics</subject><subject>Immunotherapy</subject><subject>Internal Medicine</subject><subject>Leukemia</subject><subject>Liver cancer</subject><subject>Lymphocytes</subject><subject>Lymphoma</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Oncology</subject><subject>Patients</subject><subject>Proteins</subject><subject>Transcription factors</subject><issn>2397-768X</issn><issn>2397-768X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9Us2K1TAYLaI4w3VewIUE3AhSzV-TZiXOddSBEReO4C6kadLm0jbXJBXvA_jeprfjOONCCCR838k5OV9OUTxF8BWCpH4dKWKiLiGmJYQMVyV_UJxiInjJWf3t4Z3zSXEW4w5CiOoKYcYeFyekFhWjBJ8Wv86BNsMAhsO47_2oAAP74EefTAS92avkl_Y8qAC0CtpNCyYjumBidH4CzQG4qXeNS27qQJpHH3LBuiEFdSxt39GX16uIPiSf_E-nXTqA1Ac_dz24-PIJPSkeWTVEc3azb4qv7y-utx_Lq88fLrdvr0pNeJ1KTlrFqSFUKNMQbBvOudGYVA3lyqJKCdZCVFloeaWZgC0ThAkrDGU149aQTXG58rZe7eQ-uFGFg_TKyWPBh06qkJwejNSCU4h52wpSU8GVsMRQi1vNLK50xTPXm5VrPzejabWZsuPhHun9zuR62fkfEiGMYf63zPDihiH477OJSY4uLoNSk_FzlATyinC2rE3x_B_ozs9hyrNaULSuKc1eNwVeUTr4GIOxt69BUC6pkWtqZFaXx9TIxcezuz5ur_zJSAaQFRBza-pM-Kv9H9rf-V_PYg</recordid><startdate>20240701</startdate><enddate>20240701</enddate><creator>Li, Jiatao</creator><creator>Feng, Juan</creator><creator>Li, Ziyong</creator><creator>Ni, Yuanli</creator><creator>Liu, Limei</creator><creator>Lei, Xia</creator><creator>Chai, Zixuan</creator><creator>Zhuang, Na</creator><creator>Xu, Jiake</creator><creator>He, Yongpeng</creator><creator>Shan, Juanjuan</creator><creator>Qian, Cheng</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><general>Nature Portfolio</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-0640-1652</orcidid><orcidid>https://orcid.org/0009-0006-2546-7602</orcidid><orcidid>https://orcid.org/0000-0003-1500-9991</orcidid><orcidid>https://orcid.org/0000-0002-9277-6855</orcidid></search><sort><creationdate>20240701</creationdate><title>B cell lymphoma 6 promotes hepatocellular carcinoma progression by inhibiting tumor infiltrating CD4+T cell cytotoxicity through ESM1</title><author>Li, Jiatao ; Feng, Juan ; Li, Ziyong ; Ni, Yuanli ; Liu, Limei ; Lei, Xia ; Chai, Zixuan ; Zhuang, Na ; Xu, Jiake ; He, Yongpeng ; Shan, Juanjuan ; Qian, Cheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c378t-73da74e349aeb32fb777ec235b47af15a96d015f0f75c690d69369f9e46867fe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>631/67/580/1884</topic><topic>692/4028/67/395</topic><topic>Antigens</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Cell death</topic><topic>Clinical outcomes</topic><topic>Cytokines</topic><topic>Cytotoxicity</topic><topic>DNA repair</topic><topic>Gene Therapy</topic><topic>Genomes</topic><topic>Human Genetics</topic><topic>Immunotherapy</topic><topic>Internal Medicine</topic><topic>Leukemia</topic><topic>Liver cancer</topic><topic>Lymphocytes</topic><topic>Lymphoma</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Oncology</topic><topic>Patients</topic><topic>Proteins</topic><topic>Transcription factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Jiatao</creatorcontrib><creatorcontrib>Feng, Juan</creatorcontrib><creatorcontrib>Li, Ziyong</creatorcontrib><creatorcontrib>Ni, Yuanli</creatorcontrib><creatorcontrib>Liu, Limei</creatorcontrib><creatorcontrib>Lei, Xia</creatorcontrib><creatorcontrib>Chai, Zixuan</creatorcontrib><creatorcontrib>Zhuang, Na</creatorcontrib><creatorcontrib>Xu, Jiake</creatorcontrib><creatorcontrib>He, Yongpeng</creatorcontrib><creatorcontrib>Shan, Juanjuan</creatorcontrib><creatorcontrib>Qian, Cheng</creatorcontrib><collection>SpringerOpen</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>NPJ precision oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Jiatao</au><au>Feng, Juan</au><au>Li, Ziyong</au><au>Ni, Yuanli</au><au>Liu, Limei</au><au>Lei, Xia</au><au>Chai, Zixuan</au><au>Zhuang, Na</au><au>Xu, Jiake</au><au>He, Yongpeng</au><au>Shan, Juanjuan</au><au>Qian, Cheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>B cell lymphoma 6 promotes hepatocellular carcinoma progression by inhibiting tumor infiltrating CD4+T cell cytotoxicity through ESM1</atitle><jtitle>NPJ precision oncology</jtitle><stitle>npj Precis. Onc</stitle><addtitle>NPJ Precis Oncol</addtitle><date>2024-07-01</date><risdate>2024</risdate><volume>8</volume><issue>1</issue><spage>139</spage><epage>16</epage><pages>139-16</pages><artnum>139</artnum><issn>2397-768X</issn><eissn>2397-768X</eissn><abstract>Immunotherapy exhibited potential effects for advanced hepatocellular carcinoma, unfortunately, the clinical benefits are often countered by cancer adaptive immune suppressive response. Uncovering the mechanism how cancer cells evade immune surveillance would help to develop new immunotherapy approaches and combination therapy. In this article, by analyzing the transcriptional factors which modulate the differentially expressed genes between T cell infiltration high group and low group, we identified oncoprotein B cell lymphoma 6 (BCL6) suppresses the infiltration and activation of tumor infiltrating T lymphocytes, thus correlated with poorer clinical outcome. By using antibody deletion experiment, we further demonstrated that CD4 + T cells but not CD8 + T cells are the main lymphocyte population suppressed by Bcl6 to promote HCC development. Mechanistically, BCL6 decreases cancer cell expression of pro-inflammatory cytokines and T lymphocyte chemokines such as IL6, IL1F6, and CCL5. Moreover, BCL6 upregulates Endothelial cell-specific molecule 1 (ESM1) to inhibit T lymphocyte recruitment and activation possibly through ICAM-1/LFA-1 signaling pathway. Our findings uncovered an unappreciated paracrine mechanism how cancer cell-derived BCL6 assists cancer cell immune evasion, and highlighted the role of CD4 + T cells in HCC immune surveillance.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>38956432</pmid><doi>10.1038/s41698-024-00625-7</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0002-0640-1652</orcidid><orcidid>https://orcid.org/0009-0006-2546-7602</orcidid><orcidid>https://orcid.org/0000-0003-1500-9991</orcidid><orcidid>https://orcid.org/0000-0002-9277-6855</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2397-768X
ispartof NPJ precision oncology, 2024-07, Vol.8 (1), p.139-16, Article 139
issn 2397-768X
2397-768X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_c974027dd938497a9f3e4f2dc6f25c57
source Publicly Available Content Database; PubMed Central; Alma/SFX Local Collection; Springer Nature - nature.com Journals - Fully Open Access
subjects 631/67/580/1884
692/4028/67/395
Antigens
Cancer Research
Cancer therapies
Cell death
Clinical outcomes
Cytokines
Cytotoxicity
DNA repair
Gene Therapy
Genomes
Human Genetics
Immunotherapy
Internal Medicine
Leukemia
Liver cancer
Lymphocytes
Lymphoma
Medicine
Medicine & Public Health
Oncology
Patients
Proteins
Transcription factors
title B cell lymphoma 6 promotes hepatocellular carcinoma progression by inhibiting tumor infiltrating CD4+T cell cytotoxicity through ESM1
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T16%3A48%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=B%20cell%20lymphoma%206%20promotes%20hepatocellular%20carcinoma%20progression%20by%20inhibiting%20tumor%20infiltrating%20CD4+T%20cell%20cytotoxicity%20through%20ESM1&rft.jtitle=NPJ%20precision%20oncology&rft.au=Li,%20Jiatao&rft.date=2024-07-01&rft.volume=8&rft.issue=1&rft.spage=139&rft.epage=16&rft.pages=139-16&rft.artnum=139&rft.issn=2397-768X&rft.eissn=2397-768X&rft_id=info:doi/10.1038/s41698-024-00625-7&rft_dat=%3Cproquest_doaj_%3E3075376376%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c378t-73da74e349aeb32fb777ec235b47af15a96d015f0f75c690d69369f9e46867fe3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3074884469&rft_id=info:pmid/38956432&rfr_iscdi=true